LDCA

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

LDCA 是一种双重打击代谢调节剂，可抑制 LDH-A 酶活性，刺激恶性群体的凋亡。LDCA 可用于致癌进展的研究。

LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.

LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells.Cell Viability Assay Cell Line:B16-F10 cells Concentration:2-100 μM Incubation Time:72 h Result:Arrested cell growth with a dose-dependent cytotoxic effect and had a strong synergism with LDCA.Apoptosis Analysis Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:24 h Result:Resulted 15% death when cells exposed to LDCA and caused 40% melanoma cell death combination synergistically with doxorubicin.Immunofluorescence Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Demonstrated thatcombination with doxorubicin resultantly affected cellular morphologywith condensed and fragmented nuclei.Cell Migration Assay Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Signicantly limited the migratory potential in the B16-F10 cells.

LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma.Animal Model:melanoma tumor model Dosage:2 mg/kg Administration:2 mg/kg, iv., the 6th day, once Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.

——

Apoptosis

Apoptosis

Apoptosis | Dehydrogenase

——

——

349106-80-5

256.49

C8H5Cl3FNO

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (389.88 mM; 超声助溶 (<60°C)

N(C(C(Cl)Cl)=O)C1=CC(Cl)=C(F)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years